- Home
- INCY vs FTI Comparison
INCY vs FTI Comparison
Compare INCY & FTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- FTI
- Stock Information
- Founded
- INCY 1991
- FTI 1884
- Country
- INCY United States
- FTI United States
- Employees
- INCY N/A
- FTI 22848
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- FTI Metal Fabrications
- Sector
- INCY Health Care
- FTI Industrials
- Exchange
- INCY Nasdaq
- FTI Nasdaq
- Market Cap
- INCY 13.4B
- FTI 10.9B
- IPO Year
- INCY 1993
- FTI N/A
- Fundamental
- Price
- INCY $68.07
- FTI $25.89
- Analyst Decision
- INCY Buy
- FTI Strong Buy
- Analyst Count
- INCY 19
- FTI 14
- Target Price
- INCY $74.38
- FTI $35.85
- AVG Volume (30 Days)
- INCY 1.8M
- FTI 5.3M
- Earning Date
- INCY 04-29-2025
- FTI 04-24-2025
- Dividend Yield
- INCY N/A
- FTI 0.78%
- EPS Growth
- INCY N/A
- FTI 1491.67
- EPS
- INCY 0.15
- FTI 1.91
- Revenue
- INCY $4,241,216,999.00
- FTI $9,083,300,000.00
- Revenue This Year
- INCY $12.23
- FTI $10.05
- Revenue Next Year
- INCY $8.89
- FTI $8.74
- P/E Ratio
- INCY $454.93
- FTI $13.48
- Revenue Growth
- INCY 14.76
- FTI 16.09
- 52 Week Low
- INCY $50.35
- FTI $22.08
- 52 Week High
- INCY $83.95
- FTI $33.45
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- FTI 33.11
- Support Level
- INCY $68.17
- FTI $24.62
- Resistance Level
- INCY $72.81
- FTI $27.04
- Average True Range (ATR)
- INCY 2.29
- FTI 1.24
- MACD
- INCY -0.32
- FTI -0.32
- Stochastic Oscillator
- INCY 8.61
- FTI 20.35
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FTI TechnipFMC plc
TechnipFMC is the largest pure-play offshore oilfield service provider, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea engineering and construction services. The company also provides various surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of predecessor companies Technip and FMC Technologies.